Product
IMM27M
1 clinical trial
2 indications
Indication
OncologyIndication
CTLA4 haploinsufficiencyClinical trial
A Phase 1 Study to Evaluate IMM27M Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity in Patients With Advanced, Metastatic Solid TumorStatus: Recruiting, Estimated PCD: 2023-08-30